Business · 13/05/2014
FDA Hosts Public Workshop on Enzyme Replacement Therapies and Immune Tolerance Induction
The FDA, in partnership with NORD, is hosting a public workshop to discuss the role of immune tolerance induction in patients receiving enzyme replacement therapies, a topic of interest for the National Organization for Rare Disorders and other stakeholders.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →